Glucagon‐like peptide‐1 protects synaptic and learning functions from neuroinflammation in rodents
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide‐1 (GLP‐1) is derived from the processing of proglucagon in intestinal L‐cells and releases insulin from pancreatic β‐cells as an incretin. The GLP‐1 receptor has been proposed as a possible therapeutic target for the treatment of Alzheimer's disease, in which neuroinflammation is critical in the pathogenesis. The present study investigates whether GLP‐1 (7–36) amide, an active fragment of GLP‐1, protected against synaptic impairments induced by inflammation‐related injurious agents (lipopolysaccharide [LPS], interleukin‐1β [IL‐1β], and H 2 O 2). In the Y‐maze test, LPS (10 μg/mouse, i.c.v) significantly decreased the percentage alternation. Pretreatment with GLP‐1 (7–36) amide (0.09–0.9 nmol/mouse, i.c.v.) prevented an impairment in spontaneous alternation performance. Pretreatment with LPS (10 μg/ml, 2 hr) impaired LTP induction but not paired‐pulse facilitation in the CA1 region of rat hippocampal slices. This impairment was prevented by cotreatment with GLP‐1 (7–36) amide (50 nM). IL‐1β (0.57 nM) or H 2 O 2 (50 μM) also impaired LTP induction. This impairment was prevented by GLP‐1 (7–36) amide (50 nM). These results suggest that GLP‐1 (7–36) amide improves the synaptic impairments induced by inflammation‐related injurious agents in the CA1 region of the hippocampus. © 2014 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Theta oscillations in the hippocampus
Buzsáki, G. (2002) · Neuron · doi:10.1016/s0896-6273(02)00586-x · Cited by 3,332
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Structural plasticity and memory
Lamprecht, R., & LeDoux, J. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1301 · Cited by 1,010 · cited 1×
“The early-phase LTP (E-LTP) may not require new protein synthesis as short-term memory, whereas the latephase (L-LTP), like long-term memory, may require protein synthesis and actin cytoskeletal rearrangements (Lamprecht and LeDoux, 2004; Cingolani and Goda, 2008; Huang et al., 2013).”
BackgroundActin in action: the interplay between the actin cytoskeleton and synaptic efficacy.
Cingolani, L. A., & Goda, Y. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2373 · Cited by 831 · cited 1×
“The early-phase LTP (E-LTP) may not require new protein synthesis as short-term memory, whereas the latephase (L-LTP), like long-term memory, may require protein synthesis and actin cytoskeletal rearrangements (Lamprecht and LeDoux, 2004; Cingolani and Goda, 2008; Huang et al., 2013).”
BackgroundRegulatory mechanisms of AMPA receptors in synaptic plasticity
Derkach, V. A., Oh, M. C., Guire, E. S., & Soderling, T. R. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2055 · Cited by 708
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 4×
“The concentration of GLP-1 (7–36) amide was based on previous studies in which maximal responses were obtained at 10–100 nM (G€oke et al., 1989; Perry et al., 2003; Li et al., 2009; Amato et al., 2010).”
BackgroundMethodInfluentialHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 2×
“…antidepressant-like effects in the forced swim test (Isacson et al., 2011) and increased hippocampal neurogenesis in adult rodents (Li et al., 2010; Hunter and Holscher, 2012), which is thought to be an important mechanism underlying the effects of antidepressants and mood stabilizers (Anacker et…”
BackgroundGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474
Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor
Anacker, C., Zunszain, P. A., Cattaneo, A., Carvalho, L. A., Garabedian, M. J., Thuret, S., Price, J., & Pariante, C. M. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.26 · Cited by 435 · cited 2×
“…the forced swim test (Isacson et al., 2011) and increased hippocampal neurogenesis in adult rodents (Li et al., 2010; Hunter and Holscher, 2012), which is thought to be an important mechanism underlying the effects of antidepressants and mood stabilizers (Anacker et al., 2011; Boku et al., 2011).”
BackgroundShaftel, S. S., Kyrkanides, S., Olschowka, J. A., Miller, J.-N. H., Johnson, R. E., & O’Banion, M. K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31450 · Cited by 433 · cited 2×
“IL-1b causes the upregulation of Ab and plaque production (Blasko et al., 2000; Griffin et al., 2006; Shaftel et al., 2007), enhancement of Ab-induced damage (Craft et al., 2005), neural cell death, and synaptic dysfunctions (Vereker et al., 2000b).”
BackgroundmTORC2 controls actin polymerization required for consolidation of long-term memory
Huang, W., Zhu, P. J., Zhang, S., Zhou, H., Stoica, L., Galiano, M., Krnjević, K., Roman, G., & Costa-Mattioli, M. (2013) · Nature Neuroscience · doi:10.1038/nn.3351 · Cited by 307
Blasko, I., Veerhuis, R., Stampfer-Kountchev, M., Saurwein-Teissl, M., Eikelenboom, P., & Grubeck-Loebenstein, B. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0321 · Cited by 258
The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease
Corrêa, S. A. L., & Eales, K. L. (2012) · Journal of Signal Transduction · doi:10.1155/2012/649079 · Cited by 258
Cytokines in bipolar disorder: A systematic review and meta-analysis
Munkholm, K., Vinberg, M., & Vedel Kessing, L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.06.010 · Cited by 256 · cited 2×
“Both inflammatory changes (Dowlati et al., 2010; Hannestad et al., 2011; Rawdin et al., 2012; Munkholm et al., 2013) and neurophysiological abnormalities in the hippocampus have also been observed in patients with mood disorders (Savitz et al.”
BackgroundTanaka, S., Ide, M., Shibutani, T., Ohtaki, H., Numazawa, S., Shioda, S., & Yoshida, T. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20752 · Cited by 224 · cited 2×
“It was previously reported that subacute treatment with LPS for 5 days induced learning and memory deficits without neuronal cell death (Tanaka et al., 2006) and that chronic infusion with LPS for 37 days resulted in neuronal cell loss (Hauss-Wegrzyniak et al.”
BackgroundGlucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207 · cited 2×
“We previously reported that GLP-1 (7–36) amide inhibited LPS-induced cytokine expression in cultured astrocytes (Iwai et al., 2006).”
BackgroundSelf-citationHogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191
Savitz, J., Frank, M. B., Victor, T., Bebak, M., Marino, J. H., Bellgowan, P. S. F., McKinney, B. A., Bodurka, J., Kent Teague, T., & Drevets, W. C. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.10.007 · Cited by 146 · cited 2×
“Both inflammatory changes (Dowlati et al., 2010; Hannestad et al., 2011; Rawdin et al., 2012; Munkholm et al., 2013) and neurophysiological abnormalities in the hippocampus have also been observed in patients with mood disorders (Savitz et al., 2012).”
BackgroundAmato, A., Cinci, L., Rotondo, A., Serio, R., Faussone-pellegrini, M. S., Vannucchi, M. G., & Mulè, F. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01476.x · Cited by 124
Craft, J. M., Watterson, D. M., Hirsch, E., & Van Eldik, L. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-15 · Cited by 96
Cited by
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
“Lixisenatide Neurodegenerative brain disorder [90]”
BackgroundKim, B., & Feldman, E. L. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.3 · Cited by 355
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
“Facilitating synaptic plasticity and cognitive function [38-41, 50, 147, 148, 154, 156-160, 162, 174-183].”
Inflammation meets metabolic disease: Gut feeling mediated by GLP-1
Zietek, T., & Rath, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00154 · Cited by 131
“Again emphasizing the interrelation of metabolic and inflammatory disorders, beneficial outcomes have also been observed in cardiovascular disease (67), stroke (68), hepatic diseases (69, 70), nephritis (71), neuro-inflammation (72, 73), rheumatoid arthritis (74), lung inflammation (75), and sepsis (7) (Figure 2).”
Background
Metadata
- Authors
- Iwai, T., Sawabe, T., Tanimitsu, K., Suzuki, M., Sasaki‐Hamada, S., & Oka, J.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2014-01-27
- Volume
- 92
- Issue
- 4
- Pages
- 446-454
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W1543895408
- Cited by
- 49
- References
- 20
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.